Bicycle Therapeutics (BCYC) Financials

Bicycle Therapeutics (NASDAQ: BCYC) remains a cash-rich clinical-stage biotech, but the latest results show a business still burning significant cash and generating only modest revenue. Over the last four years, the company has dramatically strengthened its balance sheet through equity financing, while operating losses and negative operating cash flow have remained substantial.

Key takeaways from the latest quarter (Q1 2026):

• BCYC ended Q1 2026 with $559.5 million in cash and equivalents, giving it a sizable liquidity buffer.
• Total current assets were $619.1 million versus only $48.9 million in current liabilities, suggesting a strong near-term liquidity position.
• The company had $554.3 million in total equity, indicating a solid balance sheet relative to liabilities.
• Revenue in Q1 2026 was only $887,000, so the business is still in an early commercialization phase.
• The company recorded an interest and investment income gain of $4.9 million, which helped offset losses but is not a substitute for operating profitability.
• Operating loss widened to $65.5 million in Q1 2026.
• Net loss was $60.8 million, or -$0.87 per share.
• Operating cash flow was a large outflow of $65.9 million for the quarter.
• Cash and equivalents fell from $648.3 million at Q3 2025 to $559.5 million at Q1 2026, reflecting continued cash burn.
• Retained earnings remained deeply negative at -$960.6 million, underscoring the company’s long history of cumulative losses.

Longer-term trend: BCYC’s revenue has been volatile but generally low, while expenses have stayed high. Quarterly revenue ranged from roughly $887,000 to $47.9 million over the period shown, but most quarters were still far below operating costs. Research and development remains the largest expense category, which is typical for biotech, but it also means profitability is likely distant unless a major commercial or clinical milestone materializes.

Expense and loss trends:

• R&D spending has begun to trend lower in the most recent periods, falling from $58.4 million in Q3 2025 to $48.9 million in Q1 2026.
• SG&A also declined from $20.9 million in Q4 2025 to $17.5 million in Q1 2026.
• Lower expenses helped, but not enough to offset the company’s very small revenue base.
• Even with lower spending, BCYC still posted a quarterly operating loss above $65 million.
• The company has not shown a sustained path to positive operating cash flow; all recent quarters were negative.

Balance sheet trend: BCYC’s balance sheet improved dramatically after a major capital raise in 2024. Cash rose from about $293.8 million in Q1 2023 to a peak near $961.4 million in Q2 2024, then began declining as operating losses accumulated. Even after that drawdown, the company still has ample cash today, which lowers near-term financing risk compared with many development-stage biotech peers.

What matters most for investors:

• BCYC still has meaningful runway thanks to its cash balance.
• The company has reduced some operating expenses versus prior quarters.
• A large portion of equity value remains tied to clinical and regulatory execution rather than current earnings power.
• Cash burn remains high, so the balance sheet will continue to erode unless revenue grows materially or expenses fall faster.
• The company is not close to profitability based on the current trend in revenue and losses.

Bottom line: Bicycle Therapeutics looks financially stable in the short term because of its cash position, but fundamentally it is still a cash-burning biotech with limited revenue and persistent operating losses. For retail investors, the stock likely remains a high-risk, catalyst-driven story where clinical progress and future commercial traction matter far more than near-term earnings.